Erratum: Refining an Alzheimer's vaccine to avoid an inflammatory response (Expert Opinion on Biological Therapy (2005) 5:6 (809-816) DOI: 10.1517/14712598.5.6.809);Refining an Alzheimer's vaccine to avoid an inflammatory response

Expert Opinion on Biological Therapy

Volumn 5, Issue 6, 2005, Pages 809-816

  Brown, Mary E ^a   DaSilva, Kevin A ^a,b   McLaurin, JoAnne ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Alzheimer's disease; Amyloid; Immunisation; Inflammation; Vaccine

Indexed keywords

ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; BAPINEUZUMAB; CHOLERA TOXIN B SUBUNIT; DNA VACCINE; EPITOPE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN; IMMUNOLOGICAL ADJUVANT; MONOCLONAL ANTIBODY; PS 80; QS 21; TETANUS TOXIN; UNCLASSIFIED DRUG; VIRUS VACCINE;

ALZHEIMER DISEASE; ANTIBODY TITER; CLINICAL TRIAL; DEGENERATIVE DISEASE; DISEASE ACTIVITY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOGENICITY; IMMUNOTHERAPY; INFLAMMATION; MENINGOENCEPHALITIS; MOUSE; NONHUMAN; REVIEW; TREATMENT OUTCOME;

EID: 21044438759     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2012.644471     Document Type: Erratum

References (69)

1. CITRON M: Alzheimer's disease: treatments in discovery and development. Nat. Neurosci. (2002) 5(Suppl.):1055-1057.
2. DAVIS KL, SAMUELS SC In: Pharmacological Management of Neurological and Psychiatric Disorders. Enna SJ, Coyle JT (Eds), McGraw-Hill, New York, USA (1998):267-316.
3. SELKOE D: Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev. (2001) 81:741-766.
4. MCLAURIN J, YANG DS, YIP CM, FRASER PE: Modulating factors in amyloid-beta fibril formation. J. Struct. Biol. (2000) 130:259-270.
5. NÄSLUND J, HAROUTUNIAN V, MOHS R et al.: Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA (2000) 283:1571-1577.
6. TERRY RD, PECK A, DETERESA R, SCHECHTER R, HOROUPIAN DS: Some morphometric aspects of the brain in senile dementia of the Alzheimer type. Ann. Neurol. (1981) 10:184-192.
7. BRAAK H, BRAAK E: Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. (1991) 82:239-259.
8. DICKSON DW, CRYSTAL HA, BEVONA C, HONER W, VINCENT I, DAVIES P: Correlations of synaptic and pathological markers with cognition of the elderly. Neurobiol. Aging (1995) 16:285-298.
9. MCLEAN CA, CHERNY RA, FRASER FW et al.: Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimers disease. Ann. Neurol. (1999) 46:860-666.
10. KLEIN WL, KRAFFT GA, FINCH CE: Targeting small Abeta oligomers: the solution to an Alzheimer's disease conundrum? Trends Neurosci. (2001) 24:219-224.
11. GONG Y, CHANG L, VIOLA KL et al.: Alzheimer's disease-affected brain: presence of oligomeric Abeta ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc. Natl. Acad. Sci. USA (2003) 100:10417-10422.
12. WALSH DN, KLYUBIN I, FADEEVA JV et al.: Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature (2002) 416:535-539.
13. SCHENK D, BARBOUR R, DUNN W et al.: Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature (1999) 400:173-177. First report to show that immunisation with Aβ1-42 results in decreased plaque load in both prevention and treatment paradigms.
14. JANUS C, PEARSON J, MCLAURIN J et al.: Abeta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature (2000) 408:979-982. Report that demonstrates that decreased amyloid due to immunisation is accompanied by enhanced behaviour.
15. MORGAN D, DIAMOND DM, GOTTSCHALL PE et al.: Abeta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature (2000) 408:982-985. Simultaneous report in a different mouse model that showed improved cognition.
16. BARD F, CANNON C, BARBOUR R et al.: Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer's disease. Nat. Meet. (2000) 6:916-919.
17. BACSKAI BJ, KAJDASZ ST, CHRISTIE RH et al.: Imaging of amyloid-β deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy. Nat. Med. (2001) 7:369-372.
18. WILCOCK DM, GORDON MN, UGEN KE et al.: Number of Aβ inoculations in APP+PSI transgenic mice influences antibody titers, microglial activation, and congophilic plaque levels. DNA Cell Biol. (2001) 20:731-736.
19. BACSKAI BJ, KAJDASZ ST, MCLELLAN ME et al.: Non-Fc-mediated mechanisms are involved in clearance of amyloid-β in vivo by immunotherapy. J. Neurosci. (2002) 22:7873-7878.
20. -/- knock-out mice. J. Neurosci. (2003) 23:8532-8538.
21. WILCOCK DM, DICARLO G, HENDERSON D et al.: Intracranially administered anti-Abeta antibodies reduce beta-amyloid deposition by mechanisms both independent of and associated with microglial activation. J. Neurosci. (2003) 23:3745-3751.
22. DEMATTOS RB, BALES KR, CUMMINS DJ et al.: Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. USA (2001) 98:8850-8855.
23. SOLOMON B, KOPPEL R, HANAN E et al.: Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer β-amyloid peptide. Proc. Natl. Acad. Sci. USA (1996) 93:452-455.
24. SOLOMON B, KOPPEL R, FRANKEL D et al.: Disaggregation of Alzheimer β-amyloid by site-directed mAb. Proc. Natl. Acad. Sci. USA (1997) 94:4109-4112.
25. FRENKEL D, SOLOMON B, BENHAR I: Modulation of Alzheimer's β-amyloid neurotoxicity by site-directed single-chain antibody. J. Neuroimmunol. (2000) 106:23-31.
26. MCLAURIN J, CECAL R, KIERSTEAD ME et al.: Therapeutically effective antibodies against amyloid-beta peptide target amyloid-beta residues 4-10 and inhibit cytotoxicity and fibrillogenesis. Nat. Med. (2002) 8:1263-1269.
27. BARD F, BARBOUR R, CANNON C et al.: Epitope and isotype specificities of antibodies to β-amyloid peptide for protection against Alzheimer's disease-like neuropathology. Proc. Natl. Acad. Sci. USA (2003) 100:2023-2028.
28. DODEL RC, HAMPEL H, DU Y: Immunotherapy for Alzheimer's disease. Lancet Neurol. (2003) 2:215-220.
29. SENIOR K: Dosing in Phase II trial of Alzheimer's vaccine suspended. Lancet Neurol. (2002) 1:3.
30. ORGOGOZO JM, GILMAN S, DARTIGUES JF et al.: Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology (2003) 61:46-54. First indication that severe side effects were present in AN-1792 clinical trials.
31. NICOLL JA, WILKINSON D, HOLMES C, STEART P, MARKHAM H, WELLER RO: Neuropathology of human Alzheimer's disease after immunization with amyloid-beta peptide: a case report. Nat. Med. (2003) 9:448-452. Case report of the first patient that died after the vaccine trial, which shows the decreased extracellular plaque load.
32. FERRER I, BOADA ROVIRA M, SANCHEZ GUERRA ML, REY MJ, COSTA-JUSSA F: Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease. Brain Pathol. (2004) 14:11-20.
33. PFEIFER M, BONCRISTIANO S, BONDOLFI L et al.: Cerebral hemorrhage after passive anti-Abeta immunotherapy. Science (2002) 298:1379. First report to demonstrate possible side effects of passive immunisation, and points to the need to determine CAA load before pursuing this treatment strategy.
34. ODDO S, BILLINGS L, KESSIAK JP, CRIBBS DH, LAFERLA FM: Aβ Immunotherapy leads to clearance of early but not late, hyperphosphorylated Tau aggregates via the proteasome. Neuron (2004) 43:321-332. First attempt to try to link Aβ clearance with changes in tau pathology.
35. BAYER AJ, BULLOCK R, JONES RW et al.: Evaluation of the safety and immunogenicity of synthetic Aβ42 (AN1792) in patients with AD. Neurology (2005)64:94-100.
36. HOCK C, KONIETZKO U, STREFFER JR et al.: Antibodies against β-amyloid slow cognitive decline in Alzheimer's disease. Neuron (2003) 38:547-554.
37. FURLAN R, BRAMBILLA E, SANVITO F et al.: Vaccination with amyloid-beta peptide induces autoimmune encephalomyelitis in C57/BL6 mice. Brain (2003) 126:285-291.
38. MASLIAH E, HANSEN L, ADAME A et al.: Aβ vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer's disease. Ann. Neurol. (2005) 64:129-131. First report to demonstrate similar pathological benefits after AN-1792 vaccination in patients that did not exhibit encephalitis.
39. LOMBARDO JA, STERN EA, MCLELLAN ME et al.: Amyloid-β antibody treatment leads to rapid normalization of plaque-induced neuritic alterations. J. Neurosci. (2003) 23:10879-10883.
40. FOX NC, BLACK RS, GILMAN S et al.: Effects of A-beta immunotherapy (AN1792) on MRI measures of brain, ventricle and hippocampal volumes in Alzheimer's disease. Neurology (2005) (In Press).
41. GILMANS, KOLLER M, BLACK RS et al.: Neuropsychological, CSF, and neuropathological effects of A-beta immunotherapy (AN1792) of Alzheimer's disease in an interrupted trial. Neurology (2005) (In Press).
42. WEINER HL, SELKOE DJ: Inflammation and therapeutic vaccination in CNS diseases. Nature (2002) 420:879-884.
43. GRUBECK-LOEBENSTEIN B, BLASKO I, MARX F, TRIEB K: Immunization with beta-amyloid: could T-cell activation have a harmful effect? Trends Neurosci. (2000) 23:114.
44. MONSONEGO A, ZOTA V, KARN A et al.: Increased T cell reactivity to amyloid beta protein in older humans and patients with Alzheimer's disease. J. Clin. Invest. (2003) 112:415-422. Identification of an epitope that is associated with decreased amyloid load and no toxicity.
45. TRIEB K, RANSMAYR G, SGONC R, LASSMANN H, GRUBECK-LOEBENSTEIN B: APP peptides stimulate lymphocyte proliferation in normals, but not in patients with Alzheimer's disease. Neurobiol. Aging (1996) 17:541-547.
46. PRIDE MW, BLACK RS, HAGEN M et al.: Evaluation of potential immunologic mechanisms in the pathogenesis of treatment-induced meningoencephalitis in Alzheimer's disease patients treated with AN1792 (QS-21). Neurobiol. Aging (2004) 25:574.
47. SEUBERT P, LEE M, BARD F et al.: Characterization of the humoral response to AN1792 immunization in AD patients. Neurobiol. Aging (2004) 25:588.
48. SPINNEY L: Update on Elan vaccine for Alzheimer's disease. Lancet Neurol. (2004) 3:5.
49. SIGURDSSON EM, SCHOLTZOVA H, MEHTA PD, FRANGIONE B, WISNIEWSKI T: Immunization with a nontoxic/nonfibrillar amyloid-beta homologous peptide reduces Alzheimer's disease-associated pathology in transgenic mice. Am. J. Pathol. (2001) 159:439-447.
50. SIGURDSSON EM, KNUDSEN E, ASUNI A et al.: An attenuated immune response is sufficient to enhance cognition in an Alzheimer's disease mouse model immunized with amyloid-b derivatives. J. Neurosci. (2005) 24:6277-6282.
51. LEVERONE JF, SPOONER ET, LEHMAN HK, CLEMENTS JD, LEMERE CA: Abeta1-15 is less immunogenic than Abeta1-40/42 for intranasal immunization of wild-type mice but may be effective for 'boosting'. Vaccine (2003) 21:2197-2206.
52. AGADJANYAN MG, GHOCHIKYAN A, PETRUSHINA I et al.: Prototype Alzheimer's disease vaccine using the immunodominant B cell epitope from β-amyloid and promiscuous T cell epitope pan HLA DR-binding peptide. J. Immunol. (2005) 174:1580-1586.
53. NEUROINFLAMMATION WORKING GROUP: Inflammation and Alzheimer's disease. Neurobiol. Aging (2000) 21:383-421.
54. MONSONEGO A, IMITOLA J, ZOTA V, OIDA T, WEINER HL: Microglia-mediated nitric oxide cytotoxicity of T cells following amyloid beta-peptide presentation to Th1 cells. J. Immunol. (2003) 171:2216-2224.
55. LEMERE CA, MARON R, SPOONER ET et al.: Nasal Abeta treatment induces anti-A beta antibody production and decreases cerebral amyloid burden in PD-APP mice. Ann. NY Acad. Sci. (2000) 920:328-331.
56. WEINER HL, LEMERE CA, MARON R et al.: Nasal administration of amyloid-beta peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease. Ann. Neurol. (2000) 48:567-579.
57. CRIBBS DH, GHOCHIKYAN A, VASILEVKO V et al.: Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with beta-amyloid. Int. Immunol. (2003) 15:505-514.
58. PUAUX AL, MICHEL ML: New gene-based approaches for an AIDS vaccine. Comp. Immunol. Microbiol. Infect. Dis. (2003) 26:357-372.
59. FINN OJ: Cancer vaccines: between the idea and the reality. Nat. Rev. Immunol. (2003) 3:630-640.
60. ZHANG J, XU S, QIN J et al.: A novel recombinant adeno-associated virus vaccine reduces behavioural impairment and beta-amyloid plaques in a mouse model of Alzheimer's disease. Neurobiol. Dis. (2003) 14:365-379.
61. BOWERS WJ, MASTRANGELO MA, STANLEY HA, CASEY AE, MILO LJ, FEDEROFF HJ: HSV amplicon-mediated Aβ vaccination in Tg2576 mice: differential antigen-specific immune responses. Neurobiol. Aging (2005) 26:393-407.
62. GHOCHIKYAN A, VASILEVKO V, PETRUSHINA I et al.: Generation and characterization of the humoral immune response to DNA immunization with a chimeric beta-amyloid-interleukin-4 minigene. Eur. J. Immunol. (2003) 33:3232-3241.
63. KIM HD, KONG FK, CAO Y et al.: Immunization of Alzheimer model mice with adenovirus vectors encoding amyloid-β protein and GM-CSF reduces amyloid load in the brain. Neurosci. Lett. (2004) 370:218-223.
64. QU B, ROSENBURG RN, LIPING L, BOYER PJ, JOHNSTON SA: Gene vaccination to bias the immune response to Amyloid-β peptide as therapy for Alzheimer's disease. Arch Neurol. (2004) 61:1859-1864.
65. SCHILTZ JG, SALZER, U, MOHAJERI MH et al.: Antibodies from a DNA peptide vaccination decrease the brain amyloid burden in a mouse model of Alzheimer's disease. J. Mol. Med. (2004) 82:706-714.
66. FRENKEL D, KATZ O, SOLOMON B et al.: Immunization against Alzheimer's β-amyloid plaques via EFRH phage administration. Proc. Natl. Acad. Sci. USA (2000) 97:11455-11459.
67. RACKE MM, BOONE LI, HEPBURN DL et al.: Exacerbation of cerebral amyloid angiopathy-associated microhaemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid-β. J. Neurosci. (2005) 25:629-636.
68. DODEL RC, DU C, DEPBOYLU C et al.: Intravenous immunoglobulins containing antibodies against β-amyloid for the treatment of Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry (2004) 75:1472-1474. Potential for a safe, well-established protocol to be effective for the treatment of AD, and one that might act via multiple mechanisms.
69. RANGAN S, LIU R, BRUNE D et al.: Degradation of β-amyloid by proteolytic antibody light chains. Biochemistry (2003) 42:14328-14334.